Advanced in Hemorrhagic Proctocolitis

Gilles Boschetti

Lyon, FR 
Advanced in Hemorrhagic Proctocolitis
Lyon, FR 
OverviewLocationsClinical Research

Overview

Gilles Boschetti practices in Lyon, France. Mr. Boschetti is rated as an Advanced expert by MediFind in the treatment of Hemorrhagic Proctocolitis. His top areas of expertise are Viral Gastroenteritis, Crohn's Disease, Colitis, Ileostomy, and Colonoscopy.

His clinical research consists of co-authoring 75 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles and participated in 3 clinical trials in the study of Hemorrhagic Proctocolitis.

Gender
Male

Locations

Lyon, France
Other Locations
Hospices Civils de Lyon
Pierre-la-treiche, France
Saint-claude-de-diray, France
Montpelier, France
Montpellier, France
Saint-etienne-de-valoux, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy.
Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy.
Enrollment Status: Terminated
Publish Date: April 10, 2024
Intervention Type: Drug
Study Drug: Valganciclovir
Study Phase: Phase 3
iDEFCO: Implementation of a Tool to Identify Social Weaknesses in the Cancer Care Pathway
iDEFCO: Implementation of a Tool to Identify Social Weaknesses in the Cancer Care Pathway
Enrollment Status: Terminated
Publish Date: November 02, 2023
Intervention Type: Other
Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel Disease
Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel Disease
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Biological
Study Drugs: Prevenar 13, Pneumo 23
Study Phase: Phase 2
VEDO-PREDIRESP Project: Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
VEDO-PREDIRESP Project: Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 4
Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Ulcerative Colitis
Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: May 23, 2023
Intervention Type: Device, Procedure
Study Phase: Not Applicable
Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease
Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease
Enrollment Status: Withdrawn
Publish Date: September 30, 2022
Intervention Type: Drug
Study Drugs: Infliximab, Adalimumab, Ustekinumab
Study Phase: Not Applicable
Pharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization
Pharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization
Enrollment Status: Completed
Publish Date: March 14, 2022
Intervention Type: Drug, Diagnostic test, Biological
Study Drug: Golimumab
Study Phase: Phase 2
View 6 Less Clinical Trials

75 Total Publications

Impact of immediate drug optimization of ustekinumab on medium term targets in Crohn's disease: results from the multicentre retrospective real-life study MUST.
Impact of immediate drug optimization of ustekinumab on medium term targets in Crohn's disease: results from the multicentre retrospective real-life study MUST.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: February 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Boschetti's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile